David Walsh

Cooley advised Kudu Dynamics, a company developing state-of-the-art cyber capabilities and nonkinetic effects against a variety of military-relevant systems, on its sale to Leidos (NYSE: LDOS), an industry and technology leader serving government and commercial customers with smarter, more efficient digital and mission innovations.

Cooley advised Atsena Therapeutics, a clinical-stage gene therapy company developing best-in-class treatments for the reversal or prevention of blindness from inherited retinal diseases, on the close of its oversubscribed $150 million Series C financing.

Cooley advised PetLab Co., a rapidly growing independent pet supplement brand headquartered in London, on its majority stake sale to BC Partners, a top international investment firm.

Cooley advised Plain, a business-to-business support platform, on its $15 million Series A.

Cooley advised AttackIQ, a leading vendor of adversarial exposure validation solutions, on its acquisition of assets from DeepSurface Security, a security posture management and vulnerability prioritization company. Partner Matt Browne led the Cooley team advising AttackIQ.